keyword
MENU ▼
Read by QxMD icon Read
search

Glulisine

keyword
https://www.readbyqxmd.com/read/27517679/clinical-effects-and-safety-of-direct-acting-insulin-analogs-in-patients-with-type-1-diabetes-a-nation-wide-observational-cohort-study
#1
Vincent Lak, Ann-Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Eliasson
INTRODUCTION: Studies comparing direct-acting insulin analogs (DAIs) in terms of effectiveness and long-term safety are scarce. Our aim was to explore these variables in clinical practice among patients with type 1 diabetes, including the elderly and those with renal impairment. METHODS: We linked four national registers in a population-based cohort study. Patients with type 1 diabetes and continuous use of all currently available DAIs (lispro, aspart, or glulisine) in 2005-2013 were monitored for up to 7...
September 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27390032/20-years-of-insulin-lispro-in-pediatric-type-1-diabetes-a-review-of-available-evidence
#2
Kevin Kaiserman, Heike Jung, Imane Benabbad, Beate Karges, Michel Polak, Myriam Rosilio
BACKGROUND: Insulin lispro, the first rapid-acting insulin analog, was developed 20 years ago and has been studied in multiple situations and various populations. OBJECTIVE: To review the literature on the use of insulin lispro in children, adolescents, and young adults. PATIENTS: Children, adolescents, and young adults with type-1-diabetes. METHODS: One hundred and twenty-two relevant publications, identified by a systematic (MEDLINE) and manual literature search, were reviewed...
July 8, 2016: Pediatric Diabetes
https://www.readbyqxmd.com/read/27222510/prandial-options-to-advance-basal-insulin-glargine-therapy-testing-lixisenatide-plus-basal-insulin-versus-insulin-glulisine-either-as-basal-plus-or-basal-bolus-in-type-2-diabetes-the-getgoal-duo-2-trial
#3
Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller
OBJECTIVE: To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS: Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization...
August 2016: Diabetes Care
https://www.readbyqxmd.com/read/27168767/access-to-medicines-for-diabetes-treatment-in-brazil-evaluation-of-health-has-no-price-program
#4
João Leopoldo Oliveira Araujo, Mariana Donato Pereira, Cristiane de Cássia Bergamaschi, Fernando de Sá Del Fiol, Luciane Cruz Lopes, Maria Inês de Toledo, Silvio Barberato-Filho
BACKGROUND: In 2011, private pharmacies associated to the Brazilian Ministry of Health provided patients with two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg glibenclamide and 500 and 850 mg metformin) free of charge. The aim was to evaluate the impact of the "Health Has No Price" Program [Saúde Não Tem Preço (SNTP)] for access to diabetes treatment medicines in Brazil. METHODS: This longitudinal and observational study is based on the number of units of oral hypoglycemic agents, insulin and insulin analogues supplied in 55,000 private pharmacies from February 1, 2010 to January 31, 2012...
2016: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/27145817/systematic-literature-review-of-use-of-blood-glucose-monitoring-in-phase-iii-clinical-studies-of-insulin-analogs
#5
Kaisa Miikkulainen, Antonio Caruso, Oliver Mast, Rongrong Zhang, Oleg Borisenko
BACKGROUND: Safe and effective insulin therapy for diabetes mellitus requires initial dose titration and regular adjustments based on blood glucose (BG) monitoring. Our objective was to explore the use of BG measurement in phase-III clinical studies of insulin analogs. These studies provide safety and efficacy information for regulatory authorities and are the basis for insulin analog regulatory approval. METHODS: A systematic review of phase-III studies of rapid-acting insulin analogs (insulin lispro, insulin aspart and insulin glulisine) and pre-mixed insulin analogs (biphasic insulin aspart and insulin lispro mix) was conducted...
May 4, 2016: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/27145344/safety-of-insulin-analogues-as-compared-with-human-insulin-in-pregnancy
#6
Yoel Toledano, Eran Hadar, Moshe Hod
INTRODUCTION: Diabetes during pregnancy may lead to maternal, fetal and neonatal complications. In order to limit unwarranted outcomes, strict glycemic control is essential. In the past, human insulin was the only insulin formulation administered in pregnancy. However, insulin analogues have also been used for this indication in recent years. AREAS COVERED: This article reviews the published data regarding the safety of insulin analogue use during pregnancy. We present the qualities, advantages and pitfalls of insulin analogue use in pregnancy compared with human insulin...
July 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27110368/beam-value-an-indicator-of-the-need-to-initiate-and-intensify-prandial-therapy-in-patients-with-type-2-diabetes-mellitus-receiving-basal-insulin
#7
Ariel Zisman, Francienid Morales, John Stewart, Andreas Stuhr, Aleksandra Vlajnic, Rong Zhou
INTRODUCTION: In patients with type 2 diabetes mellitus (T2DM) with uncontrolled glycemia despite ongoing upward titration of basal insulin, targeting postprandial hyperglycemia may be required. Nevertheless, the point at which basal insulin is fully optimized and postprandial glucose (PPG) should be targeted with additional treatment remains unclear. We report here on the BeAM value (difference between bedtime and morning blood glucose values) as an indicator of the need to target PPG...
2016: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/27026836/immune-thrombocytopenic-purpura-and-gastritis-by-h-pylori-associated-with-type-1-diabetes-mellitus
#8
Carlos Culquichicón-Sánchez, Ricardo Correa, Igor Flores-Guevara, Frank Espinoza Morales, Christian R Mejia
We present the 15th case reported worldwide and 3rd case reported in Latin America of immune thrombocytopenic purpura associated with Type 1 diabetes mellitus in Scopus, MEDLINE, and SciELO. An 11-year-old male patient of mixed ethnicity with immune thrombocytopenic purpura, Type 1 diabetes mellitus, and gastritis due to H. pylori presented to the emergency room with petechiae, ecchymosis, and gingival and conjunctival bleeding that had been worsening for the past three months. The patient had a body mass index of 18...
2016: Curēus
https://www.readbyqxmd.com/read/26978173/-use-of-human-insulin-analogues-in-young-patients-with-type-1-diabetes-mellitus-results-of-the-result-observational-program-on-the-use-of-insulin-glargine-lantus-in-combination-with-insulin-glulisine-apidra-as-a-basal-bolus-regimen
#9
N V Efremova, L L Bolotskaya, D S Atarshchikov, O N Bondarenko, A V Il'in, M V Shestakova
AIM: To implement in 2009-2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. MATERIAL AND METHODS: The program covered 100 patients aged 19 to 25 years from 7 regions of the Russian Federation, who had had DM onset at the age of 9-13 years, were using human recombinant insulins as continuous insulin therapy, and had glycated hemoglobin (HbA1c) levels of 7 to 9%...
2015: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/26869418/characterization-of-sizes-of-aggregates-of-insulin-analogs-and-the-conformations-of-the-constituent-protein-molecules-a-concomitant-dynamic-light-scattering-and-raman-spectroscopy-study
#10
Chen Zhou, Wei Qi, E Neil Lewis, John F Carpenter
To generate aggregates, 3 insulin analogs, lispro, aspart, and glulisine, were incubated without phenolic preservatives for 30 days at 37 °C. As a function of incubation time, aggregation was quantified with size exclusion chromatography, and the sizes of aggregates and the conformations of the constituent molecules were characterized with concomitant dynamic light scattering and Raman spectroscopy. During incubation, lispro was progressively converted into soluble aggregates with hydrodynamic diameters of circa 15 nm, and 95% of the native protein had aggregated at day 30...
February 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/26838553/a-case-of-type-1-diabetes-mellitus-with-which-localized-insulin-allergy-was-markedly-alleviated-by-switching-to-insulin-glulisine
#11
Kahori Watanabe, Yoshiki Kusunoki, Tomoyuki Katsuno, Rie Nakae, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Takafumi Akagami, Masayuki Miuchi, Jun-Ichiro Miyagawa, Mitsuyoshi Namba
No abstract text is available yet for this article.
October 2016: Acta Diabetologica
https://www.readbyqxmd.com/read/26774015/glp-1-ras-as-compared-to-prandial-insulin-after-failure-of-basal-insulin-in-type-2-diabetes-lessons-from-the-4b-and-get-goal-duo-2-trials
#12
F Porcellati, P Lucidi, G B Bolli, C G Fanelli
The add-on of a prandial (short-acting) GLP-1 RA to basal insulin in subjects with T2DM who fail to control A1C on basal insulin, stems from the physiological principles of post-prandial glucose homeostasis, and it is based on evidence from clinical trials. The 4B and GetGoal DUO 2 studies are the first to establish in head-to-head comparison, the efficacy and safety of short-acting GLP-1 RAs vs prandial insulin, when added-on to basal insulin glargine. In the 4B study (exenatide 2/d vs lispro 3/d) exenatide demonstrated similar efficacy vs lispro in reducing A1C to ~7...
December 2015: Diabetes & Metabolism
https://www.readbyqxmd.com/read/26604774/effectiveness-and-tolerability-of-treatment-intensification-to-basal-bolus-therapy-in-patients-with-type-2-diabetes-on-previous-basal-insulin-supported-oral-therapy-with-insulin-glargine-or-supplementary-insulin-therapy-with-insulin-glulisine-the-partner-observational
#13
MULTICENTER STUDY
Martin Pfohl, Thorsten Siegmund, Stefan Pscherer, Katrin Pegelow, Jochen Seufert
BACKGROUND: Due to the progressive nature of type 2 diabetes mellitus (T2DM), antidiabetic treatment needs to be continuously intensified to avoid long-term complications. In T2DM patients on either basal insulin-supported oral therapy (BOT) or supplementary insulin therapy (SIT) presenting with HbA1c values above individual targets for 3-6 months, therapy should be intensified. This study investigated effectiveness and tolerability of an intensification of BOT or SIT to a basal-bolus therapy (BBT) regimen in T2DM patients in daily clinical practice...
2015: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/26568812/insulin-degludec-and-insulin-aspart-novel-insulins-for-the-management-of-diabetes-mellitus
#14
REVIEW
Stephen Atkin, Zeeshan Javed, Gregory Fulcher
Patients with type 2 diabetes mellitus require insulin as disease progresses to attain or maintain glycaemic targets. Basal insulin is commonly prescribed initially, alone or with one or more rapid-acting prandial insulin doses, to limit mealtime glucose excursions (a basal-bolus regimen). Both patients and physicians must balance the advantages of improved glycaemic control with the risk of hypoglycaemia and increasing regimen complexity. The rapid-acting insulin analogues (insulin aspart, insulin lispro and insulin glulisine) all have similar pharmacokinetic and pharmacodynamic characteristics and clinical efficacy/safety profiles...
November 2015: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/26459273/comparison-of-basal-bolus-and-premixed-insulin-regimens-in-hospitalized-patients-with-type-2-diabetes
#15
RANDOMIZED CONTROLLED TRIAL
Virginia Bellido, Lorena Suarez, Maria Galiana Rodriguez, Cecilia Sanchez, Marta Dieguez, Maria Riestra, Florentino Casal, Elias Delgado, Edelmiro Menendez, Guillermo E Umpierrez
OBJECTIVE: Premixed insulin is a commonly prescribed formulation for the outpatient management of patients with type 2 diabetes. The safety and efficacy of premixed insulin formulations in the hospital setting is not known. RESEARCH DESIGN AND METHODS: In a prospective, open-label trial, we randomized general medicine and surgery patients to receive a basal-bolus regimen with glargine once daily and glulisine before meals (n = 33) or premixed human insulin (30% regular insulin and 70% NPH insulin) twice daily (n = 39)...
December 2015: Diabetes Care
https://www.readbyqxmd.com/read/26435033/impact-of-insulin-initiation-on-glycaemic-variability-and-glucose-profiles-in-a-primary-healthcare-type-2-diabetes-cohort-analysis-of-continuous-glucose-monitoring-data-from-the-initiation-study
#16
J Manski-Nankervis, C J Yates, I Blackberry, J Furler, L Ginnivan, N Cohen, A Jenkins, S Vasanthakumar, A Gorelik, D Young, J Best, D O'Neal
AIM: To use continuous glucose monitoring to examine the effects of insulin initiation with glargine, with or without glulisine, on glycaemic variability and glycaemia in a cohort of people with Type 2 diabetes receiving maximum oral hypoglycaemic agents in primary healthcare. METHODS: We conducted a post hoc analysis of continuous glucose monitoring data from 89 participants at baseline and at 24 weeks after insulin commencement. Indicators of glycaemic variability (standard deviation, J-index and mean amplitude of glycaemic excursion) and glycaemia (HbA1c , mean glucose, area under the glucose-time curve) were assessed...
June 2016: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/26431249/insulin-analogues-in-pregnancy-and-specific-congenital-anomalies-a-literature-review
#17
REVIEW
Josta de Jong, Ester Garne, Ewa Wender-Ozegowska, Margery Morgan, Lolkje T W de Jong-van den Berg, Hao Wang
Insulin analogues are commonly used in pregnant women with diabetes. It is not known if the use of insulin analogues in pregnancy is associated with any higher risk of congenital anomalies in the offspring compared with use of human insulin. We performed a literature search for studies of pregnant women with pregestational diabetes using insulin analogues in the first trimester and information on congenital anomalies. The studies were analysed to compare the congenital anomaly rate among foetuses of mothers using insulin analogues with foetuses of mothers using human insulin...
May 2016: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/26382721/expanded-test-method-for-peptides-2-kda-employing-immunoaffinity-purification-and-lc-hrms-ms
#18
Andreas Thomas, Katja Walpurgis, Laura Tretzel, Paul Brinkkötter, Eric Fichant, Philippe Delahaut, Wilhelm Schänzer, Mario Thevis
Bioactive peptides with an approximate molecular mass of 2-12 kDa are of considerable relevance in sports drug testing. Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glulisine, glargine, detemir, degludec, bovine and porcine insulin), synthetic ACTH (synacthen), synthetic IGF-I (longR(3) -IGF-I) and mechano growth factors (human MGF, modified human MGF, 'full-length' MGF)...
November 2015: Drug Testing and Analysis
https://www.readbyqxmd.com/read/26355757/potential-insulin-underdelivery-from-prefilled-and-reusable-insulin-pens-in-cases-of-premature-needle-withdrawal-a-laboratory-evaluation
#19
Michael Joubert, Aini Haddouche, Julia Morera, Anne Rod, Yves Reznik
BACKGROUND: Devices for the treatment of diabetes are not always used as recommended in good practice. Our aim was to evaluate potential insulin underdelivery in cases of premature needle withdrawal after injection with insulin pens, which is a commonly observed misuse, especially in young type 1 diabetes patients. MATERIALS AND METHODS: Potential insulin underdelivery was evaluated using five prefilled insulin pens (lispro Kwikpen(®) [Eli Lilly, Indianapolis, IN], aspart Flexpen(®) [Novo Nordisk, Bagsvaerd, Denmark], glulisine Solostar(®) [Sanofi, Paris, France], detemir Flexpen(®) [Novo Nordisk], and glargine Solostar(®) [Sanofi]) and three reusable insulin pens (Humapen(®) Luxura HD with lispro cartridge [Eli Lilly], Novopen(®) Echo with aspart and detemir cartridge [Novo Nordisk], and JuniorSTAR(®) with glulisine and glargine cartridge [Sanofi]) in a laboratory...
October 2015: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/26307899/comparison-of-basal-insulin-regimens-on-glycemic-variability-in-noncritically-ill-patients-with-type-2-diabetes
#20
RANDOMIZED CONTROLLED TRIAL
J Sonya Haw, Farnoosh Farrokhi, Dawn Smiley, Limin Peng, David Reyes, Christopher Newton, Francisco J Pasquel, Priyathama Vellanki, Guillermo E Umpierrez
OBJECTIVE: To evaluate the impact of different subcutaneous basal insulin regimens on glycemic variability (GV) and hospital complications in non-intensive care unit (ICU) patients with type 2 diabetes (T2D). METHODS: This study is a post hoc analysis of 279 general medicine and surgery patients treated with either a "Basal Bolus" insulin regimen using glargine once daily and glulisine before meals or a "Basal Plus" regimen using glargine once daily plus correction doses of glulisine before meals for glucose >140 mg/dL...
December 2015: Endocrine Practice
keyword
keyword
106075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"